Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 5/20 | 0.57 |
| ▸ | F2 | P00734 | 2/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9052993 | 0.86 | TYMS (0.65) | TYMSF2F10EDNRA | |
| SCHEMBL4134328 | 0.86 | TYMS (0.65) | TYMSF2F10EDNRA | |
| SCHEMBL29829755 | 0.86 | TYMS (0.65) | TYMSF2F10EDNRA | |
| SCHEMBL4134334 | 0.86 | TYMS (0.65) | TYMSF2F10EDNRA | |
| SCHEMBL29597077 | 0.85 | F2 (0.63) | TYMSF2F10EDNRA | |
| SCHEMBL27578159 | 0.85 | F2 (0.63) | TYMSF2F10EDNRA | |
| SCHEMBL17358280 | 0.82 | EDNRA (0.44) | TYMSF2F10BCL2MCL1 | |
| SCHEMBL6266410 | 0.81 | TYMS (0.54) | TYMSF2EDNRA | |
| SCHEMBL5706271 | 0.81 | TYMS (0.54) | TYMSF2EDNRAHDAC4HDAC10 | |
| SCHEMBL180019 | 0.80 | TYMS (0.53) | TYMSF2EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368213-A1 | Novel Inhibitors of System Xc- | THE UNIVERSITY OF MONTANA | 2015-12-24 | — | — | US | disclosed |
| US-20150368213-A1 | Novel Inhibitors of System Xc- | THE UNIVERSITY OF MONTANA | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368213-A1 | Novel Inhibitors of System Xc- | SLC7A11, SLC1A1, SLC1A2 | TYMS 2541/4885F2 4520/4885F10 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.